UK study tracking islet antibodies in children and adults
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study enrolls people with islet autoantibodies, which are early markers for type 1 diabetes. It aims to understand who develops these antibodies and how they are linked to diabetes over time. No treatment is given—you just provide blood samples and answer questions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 6 months and 70 years old
- Have tested positive for at least one islet antibody (insulin, GAD, IA2, or ZnT8) confirmed by a reference lab
- Live in the United Kingdom
- Be willing to give consent (or have a parent/guardian give consent if under 16)
- Not currently using insulin injections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using a finger-prick test instead of a standard blood draw for the oral glucose tolerance test (OGTT), which measures how your body handles sugar. It may help young people at risk for or with early type 1 diabetes avoid repeated needle sticks.
This study follows people of all ages who have a positive islet autoantibody test but no diabetes symptoms yet. It aims to track them over time to learn more about how type 1 diabetes develops, which may lead to better prevention and care.
This study tests a screening program to find early signs of type 1 diabetes in family members of people who have it. If you are a close relative, you may be able to get checked and learn about your risk.
This study follows children who are at genetic risk for type 1 diabetes or have early immune signs (autoantibodies) but do not yet need insulin. It provides extra checkups and information to catch the disease early and help families understand their child's risk.
This study measures “circulating biomarkers” (blood-based signals) in people with type 1 or type 2 diabetes, and in some people without diabetes who test positive for certain diabetes antibodies. The goal is to understand what these blood signals can tell us about diabetes development and progression.
This early study tests a new kind of donor islet transplant (UP421) designed to avoid rejection. It's for adults with long-standing type 1 diabetes who have trouble controlling blood sugar despite intensive insulin therapy.
Hear when a new Registry trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.